Recursion Pharmaceuticals, Inc.

RXRX Nasdaq SEC CIK 1601830
Follow Recursion Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $18.6M +258.5% vs same quarter last year
Net income −$119M +26.6% vs same quarter last year
EPS, diluted −$0.22 +38.9% vs same quarter last year
Operating cash flow −$77.4M +34% vs same quarter last year
Revenue by quarter
$4.5M
$14.7M
$19.2M
$5.2M
$35.5M
$6.5M
$7.7M
$18.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$800M−$600M−$400M−$200M$0$200MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$74.7M−$644.8M
FY24$58.8M−$463.7M
FY23$44.6M−$328.1M
FY22$39.8M−$239.5M
FY21$10.2M−$186.5M
FY20$4M−$87M
FY19$2.3M−$61.9M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−3000%−2000%−1000%0%1000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY255%−867.9%−863.4%
FY2423.1%−814.1%−788%
FY234.5%−785.3%−736%
FY22−21.2%−616.7%−601%
FY21100%−1795.8%−1832.2%
FY20100%−2135.7%−2196%
FY19-−2692.6%−2668.3%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$378.3M
FY24−$372.9M
FY23−$299.7M
FY22−$120.6M
FY21−$198.4M
FY20−$51.2M
FY19−$61M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Recursion Pharmaceuticals
  • Healthcare median
−3000%−2000%−1000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRecursion PharmaceuticalsHealthcare median
FY25−863.4%−30.6%
FY24−788%−47%
FY23−736%−58%
FY22−601%−80.4%
FY21−1832.2%−71.8%
FY20−2196%−62.2%
FY19−2668.3%−46.2%
FY18-−49.6%